MedPath

Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline

Phase 2
Completed
Conditions
Subjective Cognitive Decline (SCD)
Interventions
Dietary Supplement: Polyamine
Dietary Supplement: Placebo
Registration Number
NCT03094546
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

The overall objective of this study is to examine the effect of polyamine supplementation on cognitive performance and further characterization of individuals with subjective cognitive decline.

Detailed Description

Memory abilities are known to decline during aging, a process that is accelerated in pathological conditions like mild cognitive impairment (MCI) and Alzheimer's disease (AD), all of which are a growing public-health concern with devastating social and economical effects. Polyamines supplementation and corresponding up-regulation of autophagy (i.e., cellular protein degradation pathways) may be a key target of intervention against age-related memory decline. The study will investigate whether a polyamine-enriched dietary supplementation (through capsule intake) could provide positive effects on cognitive function and biomarkers of elderly individuals (60-90 years old) with subjective cognitive decline (SCD).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Cognitive healthy individuals with subjective memory decline and self-reported concerns
  • 60-90 years old
  • No manifest dementia (DSM-IV criteria)
  • No limitations in activities of daily living
  • Capacity for consent
Exclusion Criteria
  • Gluten, histamine or wheat seedling intolerance
  • Severe neurological, internal or psychological diseases
  • Advanced heart or respiratory diseases, severe arteriosclerosis, untreated thyroid disease or diabetes
  • Malignant tumors, current or past history
  • Brain tumors, stroke
  • Disorders that impair attention
  • Dementia
  • Coagulation disorder, Marcumar
  • Drug abuse or alcohol dependency
  • Current polyamine substitution

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Polyamine supplementationPolyamineIntervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
PlaceboPlaceboIntervention: Dietary Supplement Placebo: 750 mg cellulose
Primary Outcome Measures
NameTimeMethod
Change in Memory performance from neuropsychological testchange from baseline after 12 month (Prior to intervention (baseline T0) and after 12 months)

Comparing memory function in subjects with polyamine intake and placebo treatment assessed prior to intervention (pre) vs. 12 month post intervention

Secondary Outcome Measures
NameTimeMethod
Change in inflammationchange from baseline after 12 month

comparing inflammation markers derived from blood plasma assessed prior to intervention (pre) vs. 12 month post intervention

Change in Brain imaging biomarkerschange from baseline after 12 month

Multimodal analysis of biomarkers, regarding structural, functional, and perfusion-related plasticity, derived from magnet resonance imaging

Change in polyamine concentrationchange from baseline after 12 month

comparing polyamine concentration derived from blood plasma assessed prior to intervention (pre) vs. 12 month post intervention

Change in Autophagy processeschange from baseline after 12 month

Evaluate autophagy processes through blood parameters assessed prior to intervention (pre) vs. 12 month post intervention

Change in Cognitive Function (from extended neuropsychological test battery)change from baseline after 12 month

Comparing cognitive function in subjects with polyamine intake and placebo treatment assessed prior to intervention (pre) vs. 12 month post intervention

Trial Locations

Locations (1)

Charité University Medicine Berlin, CCM, Department of Neurology,

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath